載入中
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
收盤時
US$2.62
−US$0.17 · -6.09%
盤後
US$2.65
+US$0.03 · +1.15%
10月12日 下午6:21 ET
盤中時間採用ET。市場資料可能有所延遲。
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
日內區間
目前US$2.62
52週區間
目前US$2.62
盤中時間採用ET。市場資料可能有所延遲。
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
日內區間
目前US$2.62
52週區間
目前US$2.62
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 1275萬 USD | — | — | — | — |
| 毛利 | −1275萬 USD | — | — | — | — |
| 研究與開發 | 1.32億 USD | 2.09億 USD | 2.2億 USD | 2.01億 USD | 3.06億 USD |
| 銷售、一般及管理費用 | 4429.6萬 USD | 6404萬 USD | 7329.9萬 USD | 7156.1萬 USD | 5041萬 USD |
| 營業費用 | 1.78億 USD | 2.73億 USD | 2.93億 USD | 2.73億 USD | 3.57億 USD |
| 利息收入 | 384.8萬 USD | 1047.1萬 USD | 993.8萬 USD | 376.2萬 USD | 67.6萬 USD |
| 折舊和攤銷 | 1275萬 USD | 1550萬 USD | 2455.7萬 USD | 1562.5萬 USD | 1107萬 USD |
| 營業利益 | −1.91億 USD | −2.73億 USD | −2.93億 USD | −2.73億 USD | −3.57億 USD |
| 淨利 | −2.44億 USD | −2.67億 USD | −2.83億 USD | −2.69億 USD | −3.56億 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$7.00
上漲空間 167.18%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2419.39萬0.00%2.3兆 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI1500.35萬0.15%98.74億 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM1258.72萬0.02%787.4億 USD0.19%US$277.88-0.38%
Vanguard Extended Market ETFVXF761.22萬0.01%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO444.22萬0.03%139.17億 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO408.15萬0.02%180億 USD0.06%US$112.27-0.35%
iShares Biotechnology ETFIBB399.52萬0.04%108.2億 USD0.44%US$204.26-1.08%
Schwab U.S. Small-Cap ETFSCHA278.56萬0.01%218.24億 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
